LSI DTCs 2007 - Graduate Academy for tissue engineering and regenerative medicine
Lead Research Organisation:
University of Leeds
Department Name: Mechanical Engineering
Abstract
Definition: A rapidly developing area at the interfaces of engineering/physical sciences, life sciences and medicine. Includes:- cell therapies (including stem cells), three dimensional cell/ matrix constructs, bioactive scaffolds, regenerative devices, in vitro tissue models for drug discovery and pre-clinical research.Social and economic needs include:Increased longevity of the ageing population with expectations of an active lifestyle and government requirements for a longer working life.Need to reduce healthcare costs, shorten hospital stays and achieve more rapid rehabilitationAn emergent disruptive industrial sector at the interface between pharmaceutical and medical devicesRequirement for relevant laboratory biological systems for screening and selection of drugs at theearly development stage, coupled with Reduction, Refinement, Replacement of in vivo testing. Translational barriers and industry needs: The tissue engineering/ regenerative medicine industry needs an increase in the number of trained multidisciplinary personnel to translate basic research, deliver new product developments, enhance manufacturing and processing capacity, to develop preclinical test methodologies and to develop standards and work within a dynamic regulatory environment. Evidence from N8 industry workshop on regenerative medicine.Academic needs: A rapidly emerging internationally competitive interdisciplinary area requiring new blood ---------------------
Organisations
- University of Leeds (Lead Research Organisation)
- White Rose University Consortium (Project Partner)
- Intercytex (United Kingdom) (Project Partner)
- NHS BLOOD AND TRANSPLANT (Project Partner)
- Healthcare Technology KTN (Project Partner)
- Yorkshire Forward (Project Partner)
- Xiros (United Kingdom) (Project Partner)
- Gluco Ltd (Leeds Innovation Centre) (Project Partner)
- Johnson & Johnson (United Kingdom) (Project Partner)
- Medtronic (United Kingdom) (Project Partner)
- Bitecic (United Kingdom) (Project Partner)
- Pfizer (United Kingdom) (Project Partner)
- Smith & Nephew plc (UK) (Project Partner)
- CellTran Ltd (Project Partner)
People |
ORCID iD |
John Fisher (Principal Investigator) |